Gilead Sciences, Inc. (GILD)
A pharmaceutical maker, one pattern. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 24, 2026. Ranked 61 of the 95 Healthcare companies read so far, by the share within reach now.
Within reach now
19%
End of 2028
41%
Employees, annual report
17,000
Leading staffing pattern
Pharmaceutical and Medicine Manufacturing
Share of the working time within reach, long-run pace, four times in five
- Now19%
- End of 202734%
- End of 202841%
- End of 203044%
What changes for its people by the end of 2028, by its industries' figures
- Stays with people 57%
- Becomes checking a model's work 36%
- Handed over with lighter checks 4%
The filing states 17,000 employees in one business, medicines, with no count by function or country, so pharmaceutical manufacturing carries the whole workforce.
The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.
What follows from the reading
Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 34% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 57% of the working time stays with people (conversation, in-person and hands-on work), 36% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.
Headcount
17,000 employees as of December 31, 2025 (stated). Not stated; the human capital section gives no count by country (United States revenue is 71%).
The filing: “As of December 31, 2025, Gilead had approximately 17,000 employees.”
The workforce as industry patterns
| Pattern | Share | Reason, from the filing |
|---|---|---|
| Pharmaceutical and Medicine Manufacturing | 100% | All revenue is from medicines (Biktarvy 49%, Descovy, Genvoya, Yescarta, Trodelvy and others in the segment table) and the filing counts no employees by function, so pharmaceutical and medicine manufacturing carries the whole workforce by description (c), as Amgen's and Lilly's readings do. |
What the filing says about the workforce: No hourly, part-time, union or country figure stated; flexible work arrangements; an annual pay equity review; the Compensation and Talent Committee oversees human capital.
Companies read with the same leading pattern
Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.
- Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
- Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
- Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
- Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
- AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
- Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
- Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
- Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028
What the filing says about AI
6 sentences in the filing name AI. Six sentences: the FDA and the European Medicines Agency set joint AI principles for drug development in January 2026 that may lead to regulatory requirements, and risk factors name unauthorized use of AI tools in data privacy or cybersecurity incidents.
- “In January 2026, the European Medicines Agency and FDA jointly established new artificial intelligence ("AI") principles in drug development that provide broad guidance on AI use in evidence generation and monitoring across all phases of a medicine's lifecycle - from early research and clinical trials to manufacturing and drug safety.”
- “These AI principles may lead to future regulatory guidance and requirements in various jurisdictions, which could affect the use of AI in our business.”
- “Likewise, data privacy or cybersecurity incidents or breaches by employees or others, including the unauthorized use of AI tools, can result in the exposure of or misuse of sensitive data, including our intellectual property or trade secrets or the personal information of our employees, patients, customers or other business partners to unauthorized persons or to the public.”
- “Recent developments in the threat landscape include the use of increasingly sophisticated and evolving AI and machine learning tools.”
- “In her current role, the CIO is responsible for implementing enterprise-wide IT and AI strategies for the company.”
Its annual reports, year by year
Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector
- Fiscal 20210median 0
- Fiscal 20220median 0
- Fiscal 20230median 1
- Fiscal 20242median 4
- Fiscal 20256median 10
Headcount by filing year
As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.
| Period | Employees | Filed | Filing |
|---|---|---|---|
| 2025-12-31 | 17,000 | 2026-02-24 | 10-K |
| 2024-12-31 | 17,600 | 2025-02-28 | 10-K |
| 2023-12-31 | 18,000 | 2024-02-23 | 10-K |
| 2022-12-31 | 17,000 | 2023-02-22 | 10-K |
| 2021-12-31 | 14,400 | 2022-02-23 | 10-K |
| 2020-12-31 | 13,600 | 2021-02-25 | 10-K |
| 2019-12-31 | 11,800 | 2020-02-25 | 10-K |
| 2018-12-31 | 11,000 | 2019-02-26 | 10-K |
| 2017-12-31 | 10,000 | 2018-02-27 | 10-K |
| 2016-12-31 | 9,000 | 2017-02-27 | 10-K |
| 2015-12-31 | 8,000 | 2016-02-24 | 10-K |
| 2014-12-31 | 7,000 | 2015-02-25 | 10-K |
| 2013-12-31 | 6,100 | 2014-02-25 | 10-K |
| 2012-12-31 | 5,000 | 2013-02-27 | 10-K |
| 2011-12-31 | 4,500 | 2012-02-23 | 10-K |
| 2010-12-31 | 4,000 | 2011-02-28 | 10-K |
| 2009-12-31 | 3,852 | 2010-03-01 | 10-K |
| 2008-12-31 | 3,441 | 2009-02-27 | 10-K |
| 2007-12-31 | 2,979 | 2008-02-27 | 10-K |
| 2006-12-31 | 2,515 | 2007-02-27 | 10-K |
| 2005-12-31 | 1,900 | 2006-03-03 | 10-K |
| 2004-12-31 | 1,654 | 2005-03-14 | 10-K |
| 2003-12-31 | 1,425 | 2004-03-11 | 10-K |
| 2002-12-31 | 1,250 | 2003-03-14 | 10-K |
| 2001-12-31 | 1,000 | 2002-03-27 | 10-K |
| 2000-12-31 | 850 | 2001-03-20 | 10-K |
| 1999-12-31 | 760 | 2000-03-30 | 10-K405 |
| 1998-12-31 | 293 | 1999-03-22 | 10-K405 |
| 1997-12-31 | 289 | 1998-03-31 | 10-K405 |
| 1996-12-31 | 248 | 1997-03-21 | 10-K405 |
Limits of this reading
- No count by function or by country: one pattern by description (c).
- The U.S. share is not stated.
Source: the company's annual report on EDGAR, accession 0000882095-26-000006, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.
The report on Gilead Sciences, Inc., $29
This page as a document to keep, with what it does not show: the share within reach at every date on three paces and two reliabilities, a typical workforce of this shape at the stated headcount role by role and task by task (the industries' staffing, never the company's roster), where to start, what changes for the people and what they would learn, every sentence in the filing that names AI, the headcount by year, the companies read with the same leading pattern, the method and a citation line. To print or save as a PDF, open again in your browser for a year.
See the report, $29See the sample first: Walmart's report is free
Questions about this company
- How much of Gilead Sciences, Inc.'s working time is within reach of AI?
- An estimated 19% now and 41% by the end of 2028, on METR's long-run pace at four in five, from the workforce Gilead Sciences, Inc.'s own annual report describes and BLS staffing patterns for its industries, never from a roster. It is an estimate with a stated method. It is not a forecast of jobs lost or of savings, and it says nothing about what the company will do.
- How many people does Gilead Sciences, Inc. employ?
- 17,000 as of December 31, 2025, as its annual report for the period ending December 31, 2025 states.
- What kinds of work make up Gilead Sciences, Inc.'s workforce?
- Read from its annual report as a blend of 1 industry staffing pattern, the largest Pharmaceutical and Medicine Manufacturing; by those patterns the work is about 44% desk work, 14% people work and 42% body work. Each share has a one-sentence reason on this page that can be checked against the filing.
- What does Gilead Sciences, Inc.'s annual report say about AI?
- 6 sentences in the filing name AI. Its annual reports for fiscal 2021 to 2025 name it in 0, 0, 0, 2 and 6 sentences, year by year. They are counted and quoted on this page, never judged: a count says how much a filing talks about AI, not what the company does with it.
- How is this estimated?
- Claude Fable 5.1 read the annual report under the Index's written rubric (version 1) on October 19, 2026: the stated headcount, the share in the U.S. when stated, and the workforce as a blend of industry staffing patterns. The estimates are the site's industry estimates weighted by those shares, from O*NET tasks with estimated lengths and METR's measurements of how long a task AI models can finish. A company can write to info@stratussc.com to have its reading checked against its filing.
Embed these figures on your site
A small card with the share of working time within reach now and at the end of 2027, 2028 and 2030, the date and a link back. Free under CC BY 4.0; the card carries the credit.